Last reviewed · How we verify

liraglutide combined with orlistat

The Fourth Affiliated Hospital of Zhejiang University School of Medicine · FDA-approved active Small molecule

liraglutide combined with orlistat is a GLP-1 receptor agonist combined with pancreatic lipase inhibitor Small molecule drug developed by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. It is currently FDA-approved for Obesity and weight management, Type 2 diabetes mellitus with obesity.

Liraglutide stimulates GLP-1 receptors to increase insulin secretion and reduce appetite, while orlistat inhibits pancreatic lipase to reduce dietary fat absorption.

Liraglutide stimulates GLP-1 receptors to increase insulin secretion and reduce appetite, while orlistat inhibits pancreatic lipase to reduce dietary fat absorption. Used for Obesity and weight management, Type 2 diabetes mellitus with obesity.

At a glance

Generic nameliraglutide combined with orlistat
SponsorThe Fourth Affiliated Hospital of Zhejiang University School of Medicine
Drug classGLP-1 receptor agonist combined with pancreatic lipase inhibitor
TargetGLP-1 receptor (liraglutide); pancreatic and gastric lipases (orlistat)
ModalitySmall molecule
Therapeutic areaEndocrinology / Obesity
PhaseFDA-approved

Mechanism of action

Liraglutide is a GLP-1 receptor agonist that enhances postprandial insulin secretion, slows gastric emptying, and promotes satiety through central nervous system effects. Orlistat is a lipase inhibitor that blocks the absorption of approximately 25-30% of dietary fat in the gastrointestinal tract. The combination targets weight loss through complementary mechanisms: appetite suppression and metabolic enhancement via liraglutide, and reduced caloric intake via orlistat.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about liraglutide combined with orlistat

What is liraglutide combined with orlistat?

liraglutide combined with orlistat is a GLP-1 receptor agonist combined with pancreatic lipase inhibitor drug developed by The Fourth Affiliated Hospital of Zhejiang University School of Medicine, indicated for Obesity and weight management, Type 2 diabetes mellitus with obesity.

How does liraglutide combined with orlistat work?

Liraglutide stimulates GLP-1 receptors to increase insulin secretion and reduce appetite, while orlistat inhibits pancreatic lipase to reduce dietary fat absorption.

What is liraglutide combined with orlistat used for?

liraglutide combined with orlistat is indicated for Obesity and weight management, Type 2 diabetes mellitus with obesity.

Who makes liraglutide combined with orlistat?

liraglutide combined with orlistat is developed and marketed by The Fourth Affiliated Hospital of Zhejiang University School of Medicine (see full The Fourth Affiliated Hospital of Zhejiang University School of Medicine pipeline at /company/the-fourth-affiliated-hospital-of-zhejiang-university-school-of-medicine).

What drug class is liraglutide combined with orlistat in?

liraglutide combined with orlistat belongs to the GLP-1 receptor agonist combined with pancreatic lipase inhibitor class. See all GLP-1 receptor agonist combined with pancreatic lipase inhibitor drugs at /class/glp-1-receptor-agonist-combined-with-pancreatic-lipase-inhibitor.

What development phase is liraglutide combined with orlistat in?

liraglutide combined with orlistat is FDA-approved (marketed).

What are the side effects of liraglutide combined with orlistat?

Common side effects of liraglutide combined with orlistat include Nausea, Gastrointestinal disturbances (diarrhea, steatorrhea), Vomiting, Abdominal pain, Headache, Hypoglycemia (if used with other antidiabetic agents).

What does liraglutide combined with orlistat target?

liraglutide combined with orlistat targets GLP-1 receptor (liraglutide); pancreatic and gastric lipases (orlistat) and is a GLP-1 receptor agonist combined with pancreatic lipase inhibitor.

Related